FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine

The US Food and Drug Administration (FDA) should look at the risk-benefit profile of approved drugs at pre-specified times after they are put on the market, the Institute of Medicine has recommended.

via FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine | BMJ.

An NHS Athens account may be required to view this in full.